Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bacillus Coagulans for Anxiety and Depression in Functional Dyspepsia
NCT07187492Phase 4Completed
- Sponsor
- Xijing Hospital of Digestive Diseases
- Start
- Sep 2025
- Primary completion
- Mar 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in functional dyspepsia (FD), anxiety disorder and major depressive disorder (MDD) comparing The probiotic group with The placebo group (2 arms). Primary endpoint: Hospital Anxiety and Depression Scale at 4 weeks. Started Sep 2025; status: completed.
02
Drugs
bacillus coagulans
03
Conditions
functional dyspepsia (FD)anxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07187492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07187492.